|
|
|
|
| LEADER |
02912nmm a2200253 u 4500 |
| 001 |
EB000621244 |
| 003 |
EBX01000000000000000474326 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
140122 ||| eng |
| 020 |
|
|
|a 9781461308638
|
| 100 |
1 |
|
|a Opie, Lionel H.
|
| 245 |
0 |
0 |
|a Clinical Use of Calcium Channel Antagonist Drugs
|h Elektronische Ressource
|c by Lionel H. Opie
|
| 250 |
|
|
|a 1st ed. 1989
|
| 260 |
|
|
|a New York, NY
|b Springer US
|c 1989, 1989
|
| 300 |
|
|
|a 320 p
|b online resource
|
| 505 |
0 |
|
|a Basic Science: Channel-mediated calcium current in the heart. -- I -- Fundamental properties: Mechanisms, classification, sites of action. -- II -- Use and comparative properties of the three prototypical calcium antagonists in ischemic heart disease, including recommendations based on an analysis of 41 trials. -- III -- Use and comparative efficacy in hypertension and supraventricular arrhythmias. Minor indications. -- IV -- Side-effects and contraindications, drug interactions and combinations. -- V -- Second-generation agents. -- VI -- Clinical pharmacokinetics of first and second-generation agents. -- VII -- Summary Tables. -- VIII -- Epilogue. Where do we go from here?
|
| 653 |
|
|
|a Cardiology
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b SBA
|a Springer Book Archives -2004
|
| 028 |
5 |
0 |
|a 10.1007/978-1-4613-0863-8
|
| 856 |
4 |
0 |
|u https://doi.org/10.1007/978-1-4613-0863-8?nosfx=y
|x Verlag
|3 Volltext
|
| 082 |
0 |
|
|a 616.12
|
| 520 |
|
|
|a Calcium antagonists are now regarded as the most important advance in cardiac drug therapy since the advent of beta-adrenergic blocking agents. Acting ba sically as vasodilators-though with many other com plex mechanisms especially in the case of the anti arrhythmic calcium antagonists, these agents have grown in importance to become among the therapeutic agents of first choice for angina pectoris and hyper tension. The major aim of the present book is to present the clinician with the information needed for the practical use of calcium antagonists. What do all the numerous and often conflicting trials say? Do these agents really work? If so, which agent and in what dose? How do the three front runners, verapamil, nifedipine and diltia zem compare in the efficacy and side-effects with each other? How do the new second generation agents, now entering the North American market, slot in and com pare with the three first-liners? When the gloss is taken away from the advertisements, what is really left? The strong clinical bias of the present book should be complimented by further reading of books slanted towards fundamentals. One of the most important and recent of these is that by Dr Winifred Nayler (Calcium Antagonists, Academic Press, 1988). That book should be basic for essential background knowledge in the area of calcium antagonists. The important basic contribu tions of Fleckenstein deserve emphasis
|